EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases

Yu Xiang, Swapna Naik, Liyun Zhao, Jianyou Shi, Hengming Ke

Medicinal Research Reviews · 2024

DOI: 10.1002/med.22017 ↗

At a glance

Übersichtsarbeit in Medicinal Research Reviews, 2024. Written by Yu Xiang and 4 co-authors. Institution: Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People…. Major MEDLINE topics: Neurodegenerative Diseases, Phosphodiesterase Inhibitors. Cited 21 times so far (Crossref); 398 references. Funded by: National Natural Science Foundation of China.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Neurodegenerative diseases (NDs) cause progressive loss of neuron structure and ultimately lead to neuronal cell death. Since the available drugs show only limited symptomatic relief, NDs are currently considered as incurable. This review will illustrate the principal roles of the signaling systems of cyclic adenosine and guanosine 3′,5′‐monophosphates (cAMP and cGMP) in the neuronal functions, and summarize expression/activity changes of the associated enzymes in the ND patients, including cyclases, protein kinases, and phosphodiesterases (PDEs). As the sole enzymes hydrolyzing cAMP and cGMP, PDEs are logical targets for modification of neurodegeneration. We will focus on PDE inhibitors and their potentials as disease‐modifying therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, and Huntington's disease. For the overlapped but distinct contributions of cAMP and cGMP to NDs, we hypothesize that dual PDE inhibitors, which simultaneously regulate both cAMP and cGMP signaling pathways, may have complementary and synergistic effects on modifying neurodegeneration and thus represent a new direction on the discovery of ND drugs.

Subjects

MeSH terms (MEDLINE)

Neurodegenerative DiseasesPhosphodiesterase InhibitorsHumansAnimalsCyclic AMPCyclic GMPPhosphoric Diester HydrolasesSignal Transduction

Author keywords

Alzheimer's diseaseHuntington's diseaseParkinson's diseaseadenosine cyclasecAMP‐dependent protein kinasecGMP‐dependent protein kinasecyclic adenosine and guanosine 3′,5′‐monophosphatesguanosine cyclaseneurodegenerative diseasesphosphodiesterases

Substances

Phosphodiesterase InhibitorsCyclic AMPCyclic GMPPhosphoric Diester Hydrolases

Authors and institutions

  • Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and…
  • Department of Pharmacology, Yale Cancer Biology Institute, Yale University, West Haven, Connecticut, USA.
  • Department of Biochemistry and Biophysics, The University of North Carolina, Chapel Hill, North Carolina, USA.

Funding

  • National Natural Science Foundation of China

Cite

APA

Xiang, Y., Naik, S., Zhao, L., Shi, J., & Ke, H. (2024). Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases. Medicinal Research Reviews. https://doi.org/10.1002/med.22017

Vancouver

Xiang Y, Naik S, Zhao L, Shi J, Ke H. Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases. Medicinal Research Reviews. 2024. doi:10.1002/med.22017

BibTeX
@article{Xiang2024,
  author = {Xiang, Yu and Naik, Swapna and Zhao, Liyun and Shi, Jianyou and Ke, Hengming},
  title = {Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases},
  journal = {Medicinal Research Reviews},
  year = {2024},
  doi = {10.1002/med.22017}
}
Start for free →